Show Stocks and Investing Publications • Mon, April 4, 2022
• Tue, April 5, 2022
Hartaj Singh Maintained (VRTX) at Buy with Increased Target to $350 on, Apr 4th, 2022
ngh-maintained-vrtx-at-buy-with-increased-target-to-350-on-apr-4th-2022.html
Stocks and Investing on Sun, Oct 27th, 2024 by 
WOPRAIHartaj Singh of Oppenheimer, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Buy with Increased Target from $305 to $350 on, Apr 4th, 2022.
Hartaj has made no other calls on VRTX in the last 4 months.
There are 7 other peers that have a rating on VRTX. Out of the 7 peers that are also analyzing VRTX, 2 agree with Hartaj's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Brian Abrahams of "RBC Capital" Maintained at Hold and Held Target at $269 on, Thursday, March 31st, 2022
- Paul Matteis of "Stifel" Maintained at Hold with Increased Target to $222 on, Thursday, January 27th, 2022
These are the ratings of the 5 analyists that currently disagree with Hartaj
- Liisa Bayko of "Evercore ISI Group" Maintained at Buy with Increased Target to $278 on, Friday, April 1st, 2022
- Brian Skorney of "Baird" Maintained at Buy and Held Target at $240 on, Wednesday, March 23rd, 2022
- Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy and Held Target at $275 on, Thursday, January 27th, 2022
- Evan Seigerman of "BMO Capital" Upgraded from Hold to Buy and Increased Target to $274 on, Thursday, January 20th, 2022
- Mohit Bansal of "Wells Fargo" Initiated at Buy and Held Target at $270 on, Thursday, December 9th, 2021
Like: 👍